Drugs / Dendritic Cell (DC) Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06435351 | Jun 2024 → May 2029 expected | triple-negative breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02745756 | Apr 2016 → Aug 2017 | neuroblastoma | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dendritic Cell (DC) Vaccine | “Dendritic Cell (DC) Vaccine” NCT02745756 ↗ |
| Modality | Vaccine | “Keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine.” NCT02745756 ↗ |
| Route | Other | “The vaccine will be given intranodally (inguinal or axillary) under ultrasound guidance” NCT06435351 ↗ |